Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen expects generic biologics

Executive Summary

"Generic biologics will happen and I think we'll see them in Europe first," Amgen CEO Kevin Sharer told investors Feb. 25. The exec noted that generic biologics are "profoundly different" from conventional generic drugs, citing the need to conduct clinical trials and the larger required investment in manufacturing facilities as examples. Sharer expects that Amgen's Epogen (epoetin alfa) in Europe would be the company's first product to face generic competition; however, the CEO said, "from our patent lives here in the U.S. and for the newer products in Europe, it's a long way out for us"...

You may also be interested in...



BIO Likes EU Model For Follow-On Biologics; Standards Are “Appropriate”

The European Union approach to follow-on biologic products sets an "appropriate" standard, the Biotechnology Industry Organization said

Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics

FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.

'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips

Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.

UsernamePublicRestriction

Register

PS143249

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel